Critical limb ischemia: current and novel therapeutic strategies
Date
2019
Authors
Hassanshahi, M.
Khabbazi, S.
Peymanfar, Y.
Hassanshahi, A.
Hosseini-Khah, Z.
Su, Y.W.
Xian, C.J.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Journal of Cellular Physiology, 2019; 234(9):14445-14459
Statement of Responsibility
Mohammadhossein Hassanshahi, Samira Khabbazi, Yaser Peymanfar,
Alireza Hassanshahi, Zahra Hosseini‐Khah, Yu‐Wen Su, Cory J. Xian
Conference Name
Abstract
Critical limb ischemia (CLI) is the advanced stage of peripheral artery disease spectrum and is defined by limb pain or impending limb loss because of compromised blood flow to the affected extremity. Current conventional therapies for CLI include amputation, bypass surgery, endovascular therapy, and pharmacological approaches. Although these conventional therapeutic strategies still remain as the mainstay of treatments for CLI, novel and promising therapeutic approaches such as proangiogenic gene/protein therapies and stem cell-based therapies have emerged to overcome, at least partially, the limitations and disadvantages of current conventional therapeutic approaches. Such novel CLI treatment options may become even more effective when other complementary approaches such as utilizing proper bioscaffolds are used to increase the survival and engraftment of delivered genes and stem cells. Therefore, herein, we address the benefits and disadvantages of current therapeutic strategies for CLI treatment and summarize the novel and promising therapeutic approaches for CLI treatment. Our analyses also suggest that these novel CLI therapeutic strategies show considerable advantages to be used when current conventional methods have failed for CLI treatment.
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
© 2019 Wiley Periodicals, Inc.